This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Indian Patents Act, 1970 | |
|---|---|
| Name | Indian Patents Act, 1970 |
| Enacted | 1970 |
| Jurisdiction | Republic of India |
| Status | in force (amended) |
Indian Patents Act, 1970
The Indian Patents Act, 1970 is the primary statute governing intellectual property protection for inventions in the Republic of India, establishing procedures for patent filing, examination, grant, rights, and remedies. Enacted against the backdrop of post‑independence policy debates, the Act has been amended by landmark reforms, most notably the Patent (Amendment) Act, 2005, to comply with international obligations such as the Agreement on Trade‑Related Aspects of Intellectual Property Rights. The Act interfaces with institutions including the Controller General of Patents, Designs and Trade Marks, the Indian Patent Office, and judicial bodies like the Supreme Court of India and various High Courts of India.
The Act was enacted in 1970 following deliberations involving the Patents Act, 1947, the Industrial Policy Resolution, 1956, and recommendations from the Justice N. Rajagopala Ayyangar Committee. Legislative intent reflected influences from the Committee on Industrial Development and policy documents of the Planning Commission (India), aiming to reconcile industrial development with public interest similar to reforms in nations like the United Kingdom and United States. Subsequent amendments drew on international instruments such as the World Trade Organization and the TRIPS Agreement, and were shaped by high‑profile disputes adjudicated by the Calcutta High Court, the Delhi High Court, and appellate rulings of the Supreme Court of India involving litigants including multinational corporations and domestic firms like Natco Pharma and Bayer. The 2005 amendments followed consultations with bodies such as the Department of Industrial Policy and Promotion and paralleled legislative changes observed in jurisdictions like Japan and Germany.
Key statutory terms include "invention", "novelty", "inventive step", "useful", and "patentee", each of which has been interpreted through case law from tribunals and courts including the Intellectual Property Appellate Board (India) and the High Court of Madras. The Act distinguishes between "patent", "prior art", and "prior publication" drawing conceptual parallels with definitions in the European Patent Convention and the Patent Cooperation Treaty. Subject‑matter exclusions and definitions have been informed by decisions involving entities such as Cipla and Novartis AG, and by submissions from research institutions like the Council of Scientific and Industrial Research and the Indian Council of Medical Research. Statutory constructs interact with administrative offices like the Patent Office Branches in Kolkata, New Delhi, Chennai, and Mumbai.
Patentability requires compliance with statutory criteria for novelty, inventive step, and industrial applicability; exclusions encompass discoveries, mathematical methods, and methods of treatment, with parallels to exclusions under the European Patent Office jurisprudence. Sectional exemptions have been litigated in cases involving pharmaceutical innovations by firms such as GlaxoSmithKline, Roche, and Pfizer, and challenged in courts referencing principles from decisions in jurisdictions like the United States Court of Appeals for the Federal Circuit. The Act contains specific provisions for plant varieties and traditional knowledge, influenced by interactions with entities including the Protection of Plant Varieties and Farmers' Rights Authority and controversies involving Turmeric and Neem bioprospecting cases.
Procedural steps encompass filing, provisional and complete specifications, priority claims under the Paris Convention for the Protection of Industrial Property, request for examination, substantive examination, and grant, with timelines influenced by administrative practices at the Indian Patent Office. Applicants range from multinational corporations such as Microsoft and Samsung to Indian inventors and startup ecosystems incubated by institutions like the Indian Institute of Technology system and Biocon. The Act interfaces with international filing systems including the Patent Cooperation Treaty (PCT) and administrative routines involving the World Intellectual Property Organization. Oppositions—both pre‑grant and post‑grant—have been invoked by stakeholders including civil society groups, generic manufacturers, and public health advocates like Médecins Sans Frontières.
A granted patent confers exclusive rights on the patentee to prevent others from making, using, selling, or importing the patented invention, enforceable through civil remedies overseen by courts including the Delhi High Court and appellate review by the Supreme Court of India. Standard term is twenty years from the filing date in line with TRIPS obligations; issues of term extension and timely working have been litigated by firms such as Bayer and Novartis AG and monitored by agencies including the Department of Pharmaceuticals. The Act mandates annual renewal fees and contains provisions addressing "working" of patents in India to prevent non‑use, with disputes brought by entities such as Natco Pharma and public interest litigants.
Statutory provisions permit compulsory licensing and government use under specified conditions, drawing precedents from compulsory licensing regimes in jurisdictions like Brazil and Thailand. Notable compulsory license proceedings involved companies such as Bayer and Natco Pharma and engaged the Controller General of Patents, Designs and Trade Marks and judicial review in the Intellectual Property Appellate Board (India). Grounds include failure to work the invention in India, non‑availability at a reasonably affordable price, and anti‑competitive practices, with policy debates involving ministries such as the Ministry of Health and Family Welfare and international actors like the World Health Organization.
Enforcement mechanisms include civil actions for injunctions, damages, and accounts of profits pursued in courts including the Bombay High Court and the Madras High Court, alongside criminal sanctions for false marking and procedural relief before tribunals such as the Intellectual Property Appellate Board (India). Landmark litigation shaping enforcement doctrines involved parties including Cipla, Roche, and Novartis AG and led to influential rulings by the Supreme Court of India on issues of patentability, public interest, and balance between rights and access. Enforcement policy intersects with competition law cases before the Competition Commission of India and administrative actions by the Customs Department (India) to curb infringing imports.
Category:Intellectual property legislation in India